NasdaqGS:ALNYBiotechs
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26
Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after presenting extensive cardiovascular data at ACC.26. The company highlighted vutrisiran in amyloidosis and zilebesiran in hypertension, alongside new efforts to improve ATTR-CM diagnosis and care coordination.
See our latest analysis for Alnylam Pharmaceuticals.
The recent ACC.26 data and ATTR-CM care initiatives have arrived after a sharp 90 day share price return decline of 20.32%, even as the 1 year total shareholder return sits...